Revised consensus statement on the preventive and symptomatic care of patients with leukodystrophies

Laura A. Adang, Omar Sherbini, Laura Ball, Miriam Bloom, Anil Darbari, Hernan Amartino, Donna DiVito, Florian Eichler, Maria Escolar, Sarah H. Evans, Ali Fatemi, Jamie Fraser, Leslie Hollowell, Nicole Jaffe, Christopher Joseph, Mary Karpinski, Stephanie Keller, Ryan Maddock, Edna Mancilla, Bruce McClaryJana Mertz, Kiley Morgart, Thomas Langan, Richard Leventer, Sumit Parikh, Amy Pizzino, Erin Prange, Deborah L. Renaud, William B Rizzo, Jay Shapiro, Dean Suhr, Teryn Suhr, Davide Tonduti, Jacque Waggoner, Amy Waldman, Nicole I. Wolf, Ayelet Zerem, Joshua L. Bonkowsky, Genevieve Bernard, Keith van Haren, Adeline Vanderver

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Leukodystrophies are a broad class of genetic disorders that result in disruption or destruction of central myelination. Although the mechanisms underlying these disorders are heterogeneous, there are many common symptoms that affect patients irrespective of the genetic diagnosis. The comfort and quality of life of these children is a primary goal that can complement efforts directed at curative therapies. Contained within this report is a systems-based approach to management of complications that result from leukodystrophies. We discuss the initial evaluation, identification of common medical issues, and management options to establish a comprehensive, standardized care approach. We will also address clinical topics relevant to select leukodystrophies, such as gallbladder pathology and adrenal insufficiency. The recommendations within this review rely on existing studies and consensus opinions and underscore the need for future research on evidence-based outcomes to better treat the manifestations of this unique set of genetic disorders.

Original languageEnglish (US)
Pages (from-to)18-32
Number of pages15
JournalMolecular Genetics and Metabolism
Volume122
Issue number1-2
DOIs
StatePublished - Sep 2017

Fingerprint

Inborn Genetic Diseases
Preventive Medicine
Adrenal Insufficiency
Pathology
Gallbladder
Quality of Life
Therapeutics

Keywords

  • Care
  • Consensus
  • Leukodystrophy
  • Outcomes
  • Prevention
  • Therapy

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Molecular Biology
  • Genetics
  • Endocrinology

Cite this

Adang, L. A., Sherbini, O., Ball, L., Bloom, M., Darbari, A., Amartino, H., ... Vanderver, A. (2017). Revised consensus statement on the preventive and symptomatic care of patients with leukodystrophies. Molecular Genetics and Metabolism, 122(1-2), 18-32. https://doi.org/10.1016/j.ymgme.2017.08.006

Revised consensus statement on the preventive and symptomatic care of patients with leukodystrophies. / Adang, Laura A.; Sherbini, Omar; Ball, Laura; Bloom, Miriam; Darbari, Anil; Amartino, Hernan; DiVito, Donna; Eichler, Florian; Escolar, Maria; Evans, Sarah H.; Fatemi, Ali; Fraser, Jamie; Hollowell, Leslie; Jaffe, Nicole; Joseph, Christopher; Karpinski, Mary; Keller, Stephanie; Maddock, Ryan; Mancilla, Edna; McClary, Bruce; Mertz, Jana; Morgart, Kiley; Langan, Thomas; Leventer, Richard; Parikh, Sumit; Pizzino, Amy; Prange, Erin; Renaud, Deborah L.; Rizzo, William B; Shapiro, Jay; Suhr, Dean; Suhr, Teryn; Tonduti, Davide; Waggoner, Jacque; Waldman, Amy; Wolf, Nicole I.; Zerem, Ayelet; Bonkowsky, Joshua L.; Bernard, Genevieve; van Haren, Keith; Vanderver, Adeline.

In: Molecular Genetics and Metabolism, Vol. 122, No. 1-2, 09.2017, p. 18-32.

Research output: Contribution to journalReview article

Adang, LA, Sherbini, O, Ball, L, Bloom, M, Darbari, A, Amartino, H, DiVito, D, Eichler, F, Escolar, M, Evans, SH, Fatemi, A, Fraser, J, Hollowell, L, Jaffe, N, Joseph, C, Karpinski, M, Keller, S, Maddock, R, Mancilla, E, McClary, B, Mertz, J, Morgart, K, Langan, T, Leventer, R, Parikh, S, Pizzino, A, Prange, E, Renaud, DL, Rizzo, WB, Shapiro, J, Suhr, D, Suhr, T, Tonduti, D, Waggoner, J, Waldman, A, Wolf, NI, Zerem, A, Bonkowsky, JL, Bernard, G, van Haren, K & Vanderver, A 2017, 'Revised consensus statement on the preventive and symptomatic care of patients with leukodystrophies', Molecular Genetics and Metabolism, vol. 122, no. 1-2, pp. 18-32. https://doi.org/10.1016/j.ymgme.2017.08.006
Adang, Laura A. ; Sherbini, Omar ; Ball, Laura ; Bloom, Miriam ; Darbari, Anil ; Amartino, Hernan ; DiVito, Donna ; Eichler, Florian ; Escolar, Maria ; Evans, Sarah H. ; Fatemi, Ali ; Fraser, Jamie ; Hollowell, Leslie ; Jaffe, Nicole ; Joseph, Christopher ; Karpinski, Mary ; Keller, Stephanie ; Maddock, Ryan ; Mancilla, Edna ; McClary, Bruce ; Mertz, Jana ; Morgart, Kiley ; Langan, Thomas ; Leventer, Richard ; Parikh, Sumit ; Pizzino, Amy ; Prange, Erin ; Renaud, Deborah L. ; Rizzo, William B ; Shapiro, Jay ; Suhr, Dean ; Suhr, Teryn ; Tonduti, Davide ; Waggoner, Jacque ; Waldman, Amy ; Wolf, Nicole I. ; Zerem, Ayelet ; Bonkowsky, Joshua L. ; Bernard, Genevieve ; van Haren, Keith ; Vanderver, Adeline. / Revised consensus statement on the preventive and symptomatic care of patients with leukodystrophies. In: Molecular Genetics and Metabolism. 2017 ; Vol. 122, No. 1-2. pp. 18-32.
@article{a54c1cd877fb4ff88a9cca9abcab9b35,
title = "Revised consensus statement on the preventive and symptomatic care of patients with leukodystrophies",
abstract = "Leukodystrophies are a broad class of genetic disorders that result in disruption or destruction of central myelination. Although the mechanisms underlying these disorders are heterogeneous, there are many common symptoms that affect patients irrespective of the genetic diagnosis. The comfort and quality of life of these children is a primary goal that can complement efforts directed at curative therapies. Contained within this report is a systems-based approach to management of complications that result from leukodystrophies. We discuss the initial evaluation, identification of common medical issues, and management options to establish a comprehensive, standardized care approach. We will also address clinical topics relevant to select leukodystrophies, such as gallbladder pathology and adrenal insufficiency. The recommendations within this review rely on existing studies and consensus opinions and underscore the need for future research on evidence-based outcomes to better treat the manifestations of this unique set of genetic disorders.",
keywords = "Care, Consensus, Leukodystrophy, Outcomes, Prevention, Therapy",
author = "Adang, {Laura A.} and Omar Sherbini and Laura Ball and Miriam Bloom and Anil Darbari and Hernan Amartino and Donna DiVito and Florian Eichler and Maria Escolar and Evans, {Sarah H.} and Ali Fatemi and Jamie Fraser and Leslie Hollowell and Nicole Jaffe and Christopher Joseph and Mary Karpinski and Stephanie Keller and Ryan Maddock and Edna Mancilla and Bruce McClary and Jana Mertz and Kiley Morgart and Thomas Langan and Richard Leventer and Sumit Parikh and Amy Pizzino and Erin Prange and Renaud, {Deborah L.} and Rizzo, {William B} and Jay Shapiro and Dean Suhr and Teryn Suhr and Davide Tonduti and Jacque Waggoner and Amy Waldman and Wolf, {Nicole I.} and Ayelet Zerem and Bonkowsky, {Joshua L.} and Genevieve Bernard and {van Haren}, Keith and Adeline Vanderver",
year = "2017",
month = "9",
doi = "10.1016/j.ymgme.2017.08.006",
language = "English (US)",
volume = "122",
pages = "18--32",
journal = "Molecular Genetics and Metabolism",
issn = "1096-7192",
publisher = "Academic Press Inc.",
number = "1-2",

}

TY - JOUR

T1 - Revised consensus statement on the preventive and symptomatic care of patients with leukodystrophies

AU - Adang, Laura A.

AU - Sherbini, Omar

AU - Ball, Laura

AU - Bloom, Miriam

AU - Darbari, Anil

AU - Amartino, Hernan

AU - DiVito, Donna

AU - Eichler, Florian

AU - Escolar, Maria

AU - Evans, Sarah H.

AU - Fatemi, Ali

AU - Fraser, Jamie

AU - Hollowell, Leslie

AU - Jaffe, Nicole

AU - Joseph, Christopher

AU - Karpinski, Mary

AU - Keller, Stephanie

AU - Maddock, Ryan

AU - Mancilla, Edna

AU - McClary, Bruce

AU - Mertz, Jana

AU - Morgart, Kiley

AU - Langan, Thomas

AU - Leventer, Richard

AU - Parikh, Sumit

AU - Pizzino, Amy

AU - Prange, Erin

AU - Renaud, Deborah L.

AU - Rizzo, William B

AU - Shapiro, Jay

AU - Suhr, Dean

AU - Suhr, Teryn

AU - Tonduti, Davide

AU - Waggoner, Jacque

AU - Waldman, Amy

AU - Wolf, Nicole I.

AU - Zerem, Ayelet

AU - Bonkowsky, Joshua L.

AU - Bernard, Genevieve

AU - van Haren, Keith

AU - Vanderver, Adeline

PY - 2017/9

Y1 - 2017/9

N2 - Leukodystrophies are a broad class of genetic disorders that result in disruption or destruction of central myelination. Although the mechanisms underlying these disorders are heterogeneous, there are many common symptoms that affect patients irrespective of the genetic diagnosis. The comfort and quality of life of these children is a primary goal that can complement efforts directed at curative therapies. Contained within this report is a systems-based approach to management of complications that result from leukodystrophies. We discuss the initial evaluation, identification of common medical issues, and management options to establish a comprehensive, standardized care approach. We will also address clinical topics relevant to select leukodystrophies, such as gallbladder pathology and adrenal insufficiency. The recommendations within this review rely on existing studies and consensus opinions and underscore the need for future research on evidence-based outcomes to better treat the manifestations of this unique set of genetic disorders.

AB - Leukodystrophies are a broad class of genetic disorders that result in disruption or destruction of central myelination. Although the mechanisms underlying these disorders are heterogeneous, there are many common symptoms that affect patients irrespective of the genetic diagnosis. The comfort and quality of life of these children is a primary goal that can complement efforts directed at curative therapies. Contained within this report is a systems-based approach to management of complications that result from leukodystrophies. We discuss the initial evaluation, identification of common medical issues, and management options to establish a comprehensive, standardized care approach. We will also address clinical topics relevant to select leukodystrophies, such as gallbladder pathology and adrenal insufficiency. The recommendations within this review rely on existing studies and consensus opinions and underscore the need for future research on evidence-based outcomes to better treat the manifestations of this unique set of genetic disorders.

KW - Care

KW - Consensus

KW - Leukodystrophy

KW - Outcomes

KW - Prevention

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=85028450878&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028450878&partnerID=8YFLogxK

U2 - 10.1016/j.ymgme.2017.08.006

DO - 10.1016/j.ymgme.2017.08.006

M3 - Review article

C2 - 28863857

AN - SCOPUS:85028450878

VL - 122

SP - 18

EP - 32

JO - Molecular Genetics and Metabolism

JF - Molecular Genetics and Metabolism

SN - 1096-7192

IS - 1-2

ER -